Skin & Blood DNA Methylation Clock for Ex Vivo Age Estimation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing DNA methylation-based biomarkers for human cells, particularly fibroblasts, are inaccurate and incompatible with ex vivo studies, limiting the ability to effectively measure and track epigenetic aging in cells commonly used in research.
Innovation Solution
A novel DNA methylation biomarker, the 'skin & blood clock', which accurately measures the age of human fibroblasts, keratinocytes, endothelial cells, and other cell types by analyzing methylation status in 391 specific CpG loci, providing a more precise estimation of epigenetic age.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing DNA methylation-based biomarkers are used to estimate epigenetic age in human cells, then age estimation can be performed, but the accuracy is insufficient particularly for fibroblasts and ex vivo studies
Solution Approach 1:
The patent segments the genome into specific regions containing 391 CpG loci that are most informative for age estimation in fibroblasts and ex vivo models. By focusing on these segmented genomic regions rather than whole-genome analysis, the biomarker achieves higher accuracy for specific cell types while maintaining reliability across different study conditions.
Solution Approach 2:
The patent applies local quality by developing tissue-specific methylation markers tailored to fibroblasts and ex vivo systems. The 391 CpG loci were selected based on their specific methylation patterns in these cell types, creating a localized solution that optimizes measurement precision for the target application rather than using a universal marker set.
2Adaptability or versatility
If pan-tissue DNA methylation biomarkers are used, then broad applicability across different tissues is achieved, but accuracy for specific cell types like fibroblasts deteriorates
Solution Approach 1:
The patent implements dynamics by creating a flexible biomarker system that can be adapted to different ex vivo models and fibroblast sources. The 391 CpG locus framework provides a dynamic platform that maintains core accuracy for fibroblasts while allowing customization for specific research contexts, balancing specialization with adaptability.
Solution Approach 2:
The patent applies parameter changes by adjusting the methylation threshold values and weighting parameters for the 391 CpG loci based on fibroblast-specific data. This optimization of parameters improves measurement precision for fibroblasts while preserving the biomarker's versatility across different ex vivo study conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 'skin & blood clock' significantly enhances the accuracy of epigenetic age estimation in human cells, enabling effective evaluation of anti-aging interventions and forensic applications, and predicting lifespan and health outcomes based on DNA methylation patterns.
Implementation Method 1
DNA methylation (DNAm). Chronological time has been shown to elicit predictable hypo- and hyper-methylation changes at many regions across the genome
Data Source
Figure 1A~1J
Figure 2A~2I
Figure 3
AI summary
DNA methylation (DNAm) based biomarkers of aging have been developed for many tissues and organs. However, these biomarkers have sub-optimal accuracy in skin cells, fibroblasts and other cell types that are often used in ex vivo studies. To address this challenge, we analyzed DNA methylation array data sets derived from multiple sources of DNA, from which we developed a novel and highly robust DNAm age estimator (based on 391 CpGs) for human fibroblasts, keratinocytes, buccal cells, endothelial cells, lymphoblastoid cells, skin, blood, and saliva samples. The application of this new age estimator to ex vivo cell culture systems revealed that cellular population doubling is generally accompanied by an increase in epigenetic aging. The new skin & blood clock disclosed herein is useful for ex vivo and in vivo studies of human aging.